EDIT Looks 34.1% Overvalued on GF Value™ Amid Gene Editing Sector Volatility
· gurufocus.com
On September 23, 2026, Editas Medicine Inc (NASDAQ: EDIT) shares declined nearly 5% following Anthropic's announcement of a novel CRISPR-like enzyme system disc
On September 23, 2026, Editas Medicine Inc (NASDAQ: EDIT) shares declined nearly 5% following Anthropic’s announcement of a novel CRISPR-like enzyme system di...